ATLASATLAS fair value
ATLAS has no fair value for this stock today.
Spero Therapeutics (SPRO)
Spero Therapeutics stock price today, ATLAS forecast and fair value
Healthcare · Biotechnology · NASDAQ
$1.14▲ +6.54%
Prices as of Oct 27, 2026 · USD
Chance of rising in 1 month
47%
that it ends higher than today in 21 sessions
0%coin flip 50%100%
This is just the summary. See everything on Spero Therapeutics in ATLAS
ATLAS's own quantitative analysis, all in one place.
- Simulation and expected rangeThousands of simulated scenarios: how far the price could rise or fall.
- Officers and shareholdersWho runs the company and which funds hold its shares.
- Customer and supplier mapWho it does business with, from its own filings.
- ATLAS builds your portfolioAnswer a short test and get portfolios that fit you.
- AlertsWe let you know when something changes in your stocks.
See everything included
- Valuation and financialsFair value step by step, quarterly accounts and upcoming events.
- NewsThe latest on the company, in one place.
- Crisis simulatorHow your portfolio would do in a crash like 2008.
- Practice risk-free$10,000 in virtual money to invest at real prices.
- Global screenerSearch US stocks and stocks from 47 countries with filters.
On Spero Therapeutics
- Simulation and expected rangeThousands of simulated scenarios: how far the price could rise or fall.
- Officers and shareholdersWho runs the company and which funds hold its shares.
- Customer and supplier mapWho it does business with, from its own filings.
- Valuation and financialsFair value step by step, quarterly accounts and upcoming events.
- NewsThe latest on the company, in one place.
And for you
- ATLAS builds your portfolioAnswer a short test and get portfolios that fit you.
- AlertsWe let you know when something changes in your stocks.
- Crisis simulatorHow your portfolio would do in a crash like 2008.
- Practice risk-free$10,000 in virtual money to invest at real prices.
- Global screenerSearch US stocks and stocks from 47 countries with filters.
Plans from €3.99 a month.
ATLAS's model gives Spero Therapeutics a 47% chance of finishing higher a month from now (21 trading sessions) than today: close to a coin flip.
In half of the simulated outcomes the price ends between $1.01 and $1.26; in 9 out of 10, between $0.83 and $1.53. Estimated annual volatility is 64%.
Price, last 12 months (weekly close)
Key numbers
- Market cap
- $69.3M
- P/E ratio
- 9.4
- 52-week high
- $3.08
- 52-week low
- $1.04
- Revenue (12 months)
- $47.0M
- Revenue growth (YoY)
- +117.6%
- Gross margin
- 0.0%
- Operating margin
- 12.0%
- Net margin
- 14.4%
- Return on equity
- 19.2%
- Free cash flow (12 months)
- $28.8M
- Beta
- 1.48
What this means
ATLAS does not publish a fair value for SPRO right now, but it does show its odds of rising: close to a coin flip.
Over the last 52 weeks SPRO has traded between $1.04 and $3.08. Today it is 63.0% below that high and 10% above its low.
On the business: revenue grew 117.6% year over year; net margin is 14.4%; it trades at 9.4 times earnings.
Its beta is 1.48: it tends to move more than the market, both up and down.
About the company
Spero Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing treatments for multi-drug resistant bacterial infections and rare diseases.
Want to see everything about Spero Therapeutics?
Get started →Plans from €3.99 a month.
Comparable companies
Other companies in the same line of business:
Frequently asked questions
What does Spero Therapeutics do?
Spero Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing treatments for multi-drug resistant bacterial infections and rare diseases.
What is the chance SPRO goes up next month?
47%: close to a coin flip. In half of the simulated outcomes, SPRO ends the month between $1.01 and $1.26.
How big is Spero Therapeutics and what is its P/E ratio?
Spero Therapeutics's market capitalization is $69.3M. Its price-to-earnings (P/E) ratio is 9.4: you pay $9.4 for each $1 of yearly earnings.
How volatile is SPRO?
ATLAS estimates annual volatility at 64%. In a typical month, half of the outcomes end between $1.01 and $1.26.
Not investment advice. ATLAS estimates are produced by statistical models from public data; they can be wrong and past performance does not predict future results. Consider your own situation before investing. Disclaimer